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Abstract
Androgen receptor (AR) is a member of the nuclear receptor family of transcription factors. Upon binding to androgens, AR
becomes transcriptionally active to regulate the expression of target genes that harbor androgen response elements (AREs)
in their promoters and/or enhancers. AR is essential for the growth and survival of prostate cancer cells and is therefore a
target for current and next-generation therapeutic modalities against prostate cancer. Pathophysiologically relevant
protein-protein interaction networks involving AR are, however, poorly understood. In this study, we identified the protein
FUsed/Translocated in LipoSarcoma (FUS/TLS) as an AR-interacting protein by co-immunoprecipitation of endogenous
proteins in LNCaP human prostate cancer cells. The hormonal response of FUS expression in LNCaP cells was shown to
resemble that of other AR co-activators. FUS displayed a strong intrinsic transactivation capacity in prostate cancer cells
when tethered to basal promoters using the GAL4 system. Chromatin immunoprecipitation experiments showed that FUS
was recruited to ARE III of the enhancer region of the PSA gene. Data from ectopic overexpression and ‘‘knock-down’’
approaches demonstrated that AR transcriptional activity was enhanced by FUS. Depletion of FUS reduced androgen-
dependent proliferation of LNCaP cells. Thus, FUS is a novel co-activator of AR in prostate cancer cells.
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Introduction
Androgen receptor (AR) is required for the survival and growth
of prostate cancer cells. Accordingly, advanced prostate cancer can
be treated with androgen ablation therapies. Unfortunately, these
therapies eventually fail and the disease becomes lethal, castration-
resistant prostate cancer (CRPC). The most widely supported
mechanism underlying CRPC involves AR. The amino-terminus
domain (NTD) of AR is required for both ligand-dependent and
ligand-independent activity of the receptor (for a review see [1]).
Thus, current efforts to develop more effective drugs against
CRPC are focused on more effective blockage of androgen
synthesis, antiandrogens that competitively bind the AR ligand-
binding domain (LBD) with much higher affinity [2], and
inhibitors of the AR NTD [3]. Continued efforts to develop drugs
would benefit from improved understanding of the protein-protein
interaction networks involving the AR. To this end, we employed
a proteomic approach and identified novel endogenous AR
interaction partners in prostate cancer cells that include members
of a group of proteins called FET/TET. This family of proteins
includes: FUsed in Sarcoma (FUS)/Translocated in LipoSarcoma
(TLS), EWig’s Sarcoma protein (EWS), and the TATA binding
Protein-Associated Factor, TAF15.
FET proteins display diverse functions including transcriptional
modulation, splicing, cell spreading, and DNA repair. FET proteins
have similar transcriptional activation domains (TADs) at their
NTD and RNA recognition motif (RRM) and repeats of the
tripeptide RGG at their carboxyl terminus [4,5]. The TAD of FET
proteins contains XYXXQ-rich motif, X being a small amino acid
(Gly, Ala, Ser or Pro) [6]. This motif is also shared with the proto-
oncoprotein SYT, the human nuclear receptor co-activator SYT-
interacting Protein/Co-activator Activator (SIP/CoAA), and SWI/
SNF/BAF250 [6]. FET NTDs, including the potent TADs, are
fused to DNA-binding domains (DBDs) of various transcription
factors in a subclass of sarcomas and other cancers [5], which leads
to hyperactivation of corresponding transcriptional activity. Emerg-
ing evidence suggests that native, full-length FET proteins bind to
and activate the functions of specific transcription factors in part by
recruiting co-factors such as CBP/p300 [4–5].
Results
AR and FUS are found in the same protein complex
LNCaP human prostate cancer cell line [7] recapitulates
important features of prostate cancer including expression of both
prostate-specific antigen (PSA) and AR as well as sensitivity to
androgen. For our initial screen, we used nuclear lysates from
LNCaP cells that were treated with the synthetic androgen
R1881 (10 nM) for 3 hrs. The lysates were immunoprecipitated
with anti-AR antibody and samples were subjected to multidi-
mensional protein identification technology (MudPIT) [8]. Mass
spectrometric analysis identified FUS, which belongs to the FET
family of proteins interacting with AR (Figure 1 A, Figure S1,
Figure S2 and Table 1). Co-immunoprecipitation (co-IP)
experiments followed by Western blot analysis validated interac-
tion between AR and FUS (Figure 1B). AR co-immunoprecip-
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isotype IgG control did not pull-down AR or FUS. Reverse co-
IP with anti-AR followed by Western blot analysis with anti-FUS
antibody also showed that AR interacted with FUS (Figure 1C).
Consistent with previous reports, treatment with R1881
enhanced levels of AR protein. In vivo association of FUS with
AR was confirmed using extracts of LNCaP xenografts that were
grown in mice before or after castration (Figure 1D). Together
Figure 1. AR and FUS are found in the same complex in LNCaP cells. (A) Identification of FUS as an AR-interacting protein by co-
immunopreciptation (Co-IP) followed by mass spectrometry (MS). MS/MS spectra of m/z 1660.77 (from 831.39, 2+) of FUS and two others shown in
supplementary material were unambiguously assigned the identified sequence LKGEATVSFDDPPSAK, APKPDGPGGGPGGSHMGGNYGDDR, and
TGQPMINLYTDR, respectively. (B) Validation of AR-FUS interaction using Co-IP followed by western blot analysis. LNCaP cells in culture were induced
with 10 nM R1881 for 6 hrs and whole lysates were used for IP with anti-FUS antibody followed by anti-AR western blot (WB) analysis. (C) Reverse IP
with anti-AR followed by WB with anti-FUS antibody. (D) IP of endogenous complexes of AR and FUS from subcutaneous LNCaP xenografts. Tumours
were harvested from intact mice (I), 10 days after castration (C10) or 30 days after castration (C30). Lysates from these tumors were individually used
for IP with anti-AR antibody followed by WB with indicated antibodies.
doi:10.1371/journal.pone.0024197.g001
Table 1. Analysis of mass spectrometric data for FUS and AR.
Acc
a Desc
b Ex_mz
c Ex_z
d Ex_mr
e Score
f Miss
g Sequence
h
IPI00221354 FUS 704.8295 2 1407.6445 57.44 0 TGQPMINLYTDR
751.6276 3 2251.8608 63.47 0 APKPDGPGGGPGGSHM- GGNYGDDR
831.3902 2 1660.7658 40.59 1 LKGEATVSFDDPPSAK
IPI00333533 AR 574.2814 2 1146.5482 40.82 0 VPYPSPTCVK
669.8026 2 1337.5906 72.36 0 SGALDEAAAYQSR
778.3500 2 1554.6855 102.57 0 DNYLGGTSTISDNAK
1076.9564 2 2151.9054 110.15 0 LQEEGEASSTTSPTEET- TQK
aAcc, protein accession number searched in IPI_human database;
bDesc, protein description;
cEx_mz, experimental peptides m/z value;
dExp_z, experimental peptides charge state;
eEx_mr, experimental peptides molecular weight;
fScore, peptide score acquired from Mascot search;
gMiss, the number of missing cleavage;
hSequence, Identified peptide sequences.
doi:10.1371/journal.pone.0024197.t001
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complex in prostate cancer cells.
Subcellular localization of FUS in prostate cancer cells
FET proteins can be localized divergently in the nucleus and/or
cytoplasm [5,9]. Immunofluorescence microscopy using antibodies
targeted against endogenous proteins was performed in LNCaP cells.
FUS was exclusively localized to the nucleus (Figure 2A). FUS
appeared to be localized in distinct speckles within the nucleus
(Figure 2A, B). Heterogeneity in sub-nuclear distribution of FUS
amongst the cell population was observed (Figure 2A, B). Dual staining
showed co-localization of AR with FUS (Figure 2B) in LNCaP cells
that were treated with 10 nM R1881 for 3 hrs. Pearson’s coefficient
approached 0.8 in some cells within specific regions of nuclei.
FUS has intrinsic transactivation activity in prostate
cancer cells
The TADs of FET proteins can confer robust transcriptional
transactivation in some tumors [4–5], but this has not been
explored in prostate cancer cells. Here, we employed the GAL4
transactivation assay to explore if transactivation activity could be
attributed to FUS in prostate cancer cells. Chimeric constructs
harboring full-length FUS (or fragments therein) fused to the Gal4-
DBD were used for this assay (Figure 3A). PC3 prostate cancer
cells, devoid of functional AR, were co-transfected with each of the
Gal4 fusion constructs, and a reporter gene containing the
minimal Gal4-binding sites (p56Gal4UAS-TATA-luciferase).
GAL4-DBD alone was used as a negative control and it had
minimal activity (Figure 3B). In contrast, Gal4-FUS induced
luciferase activity significantly (Figure 3B) which was consistent
with it having intrinsic transactivation activity. To begin to
delineate which domain (s) account for this intrinsic transactivation
capacity, we employed two constructs. The first construct had the
NTD transactivation domain (FUS-N) and the other contained the
carboxyl terminal RRM and RGGs (FUS-C) (Figure 3A). Both
fragments displayed activities that were comparable to full-length
FUS (Figure 3B). To assess the promoter context dependency of
these activities, we employed a different reporter containing the
minimal GAL4 binding sites and a TATA element, which were
juxtaposed into the E1a promoter. Similar, albeit generally higher,
transactivation capacity was observed in the context of this
promoter as in the minimal promoter (Figure 3C). Strong
transactivation capacity of the GAL4-FUS fusions was also
demonstrated in LNCaP cells (Figure 3D).
FUS promotes AR transcriptional activity in prostate
cancer cells
Having demonstrated a transactivation capacity of FUS that
was independent of the promoter in prostate cancer cells as
described above, we next evaluated the involvement of FUS
specifically in AR transcriptional activity at target genes. Two
different siRNAs targeting independent regions of the cognate
mRNA were employed to deplete the levels of FUS. AR activity
was measured in co-transfected LNCaP cells using the PSA
(6.1 kb)-luciferase reporter gene construct. This reporter contains
the PSA promoter and enhancer regions harboring several AREs
that confer induction by androgens [10–11] in an AR-dependent
manner [12–13]. Relative to the control, R1881 induction of
luciferase activity was significantly reduced upon depletion of FUS
without reducing levels of AR (Figure 4A). To corroborate these
findings with an over-expression approach, we co-transfected AR
expression vector, the ARR3-tk-LUC reporter plasmid, and
various amounts of a plasmid allowing His-tagged FUS expression
into HEK293 cells. The ARR3-tk-LUC reporter contains six
AREs and is highly inducible by androgens. Overexpression of
FUS increased AR transcriptional activity measured as luciferase
activity from ARR3-tk-LUC in a dose-dependent manner
(Figure 4B, upper and middle panels). His-FUS did not
significantly alter the transcriptional activity at the pRL-tk-LUC,
which solely contains the thymidine kinase (tk) basal promoter
(Figure 4B, lower panel).
To determine if FUS increases expression of endogenous genes,
levels of protein and mRNA of known androgen-regulated genes
were next measured. PSA mRNA and mRNA from five other
androgen-inducible genes were significantly reduced upon deple-
tion of FUS (Figure 5A). TMPRSS2 mRNA was reduced by only
one of the siRNAs, and the androgen-repressed gene, CAMK2N1
was not affected by any of the siRNAs (data not shown). Consistent
with reduced levels of mRNA, levels of PSA protein were
significantly reduced in LNCaP cells upon depletion of FUS
Figure 2. Subcellular localization of FUS in prostate cancer cells. (A) Nuclear localization of FUS in LNCaP cells. Cells were treated with R1881
(10 nM) for 3 hrs. Confocal immunofluoresence was performed using anti-FUS antibody (green) and cells were counterstained with DAPI (blue). (B)
Colocalization of AR and FUS. Dual staining shows co-localization of AR (red) with FUS (green) in LNCaP cells treated with 10 nM R1881 for 3 hrs. The
inset in the right panel represents the cell designated with (*) after threshold gating to remove the bright central green spot.
doi:10.1371/journal.pone.0024197.g002
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AR in response to androgen, chromatin immunoprecipitation
(ChIP) assay was performed. Immunoprecipitation of cross-linked
protein-DNA complexes using an antibody to FUS followed by
amplification of ARE III of the PSA gene revealed that FUS was
recruited to this ARE (Figure 5C). Collectively, these data suggest
that FUS enhances AR activity, at least at some target genes,
consistent with the strong intrinsic transactivation function
attributed to FUS (Fig. 3).
Depletion of FUS reduces proliferation of LNCaP cells
AR is essential for the growth of LNCaP cells [14]. To assess if
decreased AR activity upon depletion of FUS would result in
decreased proliferation, we performed cell-cycle analysis using flow
cytometry. As expected, R1881 (0.1 nM) increased the population
of cells in S-phase (data not shown) which was reduced by ,30%
upon depletion of FUS (Figure 6A). Noteworthy, the data was
obtained from transient transfection of siRNA resulting in relatively
inefficient depletion of FUS (Figure 6B). These data implicate a pro-
growth function of FUS on androgen-dependent proliferation,
which is consistent with increased AR transcriptional activity.
Hormone-responsiveness of FUS expression
Expression of some AR co-activators such as steroid receptor
co-activators (SRCs) is modulated by androgens and/or AR [15–
17] as part of what appears to be a network of feed-forward and
feed-back mechanisms. FUS expression, at the mRNA (Figure 7A,
upper panel) and protein levels (Figure 7A, middle panel), was
repressed in vitro in LNCaP cells after 48 hrs treatment with 10 nM
R1881. Treatment of LNCaP cells with 0.1 nM R1881 for
equivalent period of time (48 hrs), however, had negligible effects
on expression of FUS expression (Figure 7A, lower panel).
Immunohistochemistry was employed to evaluate FUS gene
expression in LNCaP xenografts. Tumor samples were prepared
from intact (non-castrated) and castrated mice (10 days post-
castration). Consistent with the in vitro data with 10 nM R1881,
castration resulted in increased expression of FUS (Figure 7B).
FUS expression tends to be higher in prostate carcinoma
versus benign tissue
To determine if the expression of FUS is altered in cancer
relative to benign prostate tissue, Oncomine database analysis was
performed using seven different clinical cohorts. Expression of
FUS was elevated in prostate carcinoma compared to benign
tissue using data from three studies (Figure 7C). However, in four
additional studies of comparable size, there was no significant
difference between levels of FUS mRNA in prostate carcinoma
compared to levels in benign prostatic tissue.
Discussion
AR is essential for all phases of prostate cancer progression
including the terminal CRPC stage. Underlying this role of AR is
Figure 3. Intrinsic transactivation potential of FUS in prostate cancer cells. (A) Chimeric constructs of full-length FUS, N- or C-fragments of
FUS fused to the Gal4 DBD. TAD=Transactivation domain; RRM=RNA recognition motif; RGG=repeats of a tripeptide containing arginine and two
glycines. (B) Transactivation activity of FUS in PC3 prostate cancer cells. PC-3 cells in 6-well plates were co-transfected with 50–100 ng of Gal4
chimera, and 1 ug of the reporter gene pFR-LUC that contains GAL4 binding sites and a TATA element. GAL4 DBD alone served as a negative control.
2 ug PGL2 empty plasmid was added to all DNA mixes. (C) As in (B) but the reporter plasmid contained Gal4-binding sites and TATA element
juxtaposed into E1a promoter. (D) As in (B) but with LNCaP instead of PC-3 cells. Columns=mean 6 standard deviation. *P,0.05, n=3.
doi:10.1371/journal.pone.0024197.g003
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repressors. The scope of pathophysiologically relevant protein-
protein interaction involving AR in prostate cancer cells is,
however, not fully known. Here, we show for the first time that
FUS interacted with AR endogenously in prostate cancer cells
and further revealed the following: (1) FUS had intrinsic
transactivation capacity in prostate cancer cells; (2) FUS
enhanced AR-mediated transcription; (3) depletion of FUS
reduced levels of expression of androgen-induced genes; (4)
FUS was recruited to AREs in response to androgen; (5)
reduction of levels of FUS limited androgen-induced prolifera-
tion; (6) levels of FUS were altered by androgen status in vitro and
in vivo; and (7) levels of FUS were elevated in clinical samples of
prostate cancer.
The DNA-binding domains (DBD) steroid receptors display
high sequence homology (e.g. AR DBD has 77% and 57%
sequence similarity with those of glucocorticoid receptor and
estrogen receptor, respectively), and can interact with many of the
same coactivators. Using recombinant proteins, FUS has been
shown to interact with the DBDs of retinoid X, estrogen, thyroid,
and glucocorticoid receptors, but AR was not examined [18].
Binding of FUS to DBDs of other hormone receptors did not
interfere with DNA-binding activities, although the role of FUS in
their transcriptional activities was not assessed [18].
Here, we demonstrate that FUS harbors strong transactivation
domains that were functional in prostate cancer cells. The C-
terminal region containing the RRM and RGG motifs of EWS
can suppress the transactivation capacity of the NTD in rabbit
kidney-derived RK-13 cells [19]. In contrast, here no suppressive
function of the C-terminal region was observed when comparing
full-length FUS to the FUS 1–273 fragment that lacks the C-
terminal RRM and RGG motifs. Furthermore, FUS 274–526 that
contains the RRM and RGG motifs but not the TAD, displayed a
strong transactivation capacity. Similar structure-function rela-
tionship data involving FUS were previously reported using the
human embryonic kidney 293 cells [20]. Thus, there are
functional transactivation domains in FUS other than those found
in its NTD at least in prostate cancer and 293 cells. Discrepancies
in the literature between FUS and EWS transactivation domains
may be cell-specific or reflect domain divergence (45% identity;
Figure 4. Levels of FUS alter AR transcriptional activity. (A) Depletion of FUS correlates with decreased AR activity. Levels of FUS were
decreased in LNCaP cells using siRNAs targeting two different regions of the respective mRNAs and subsequently transfected with 1 ug of plasmid for
PSA(6.1)-luciferase. 2 ug p-LUC empty plasmid was added to all siRNA/DNA mixes. Amounts are per well in a 6-well plate. Cells were treated with
10 nM R1881 for 24 hrs. Western blot analysis of the corresponding samples show levels of FUS, AR, and Actin. (B) Ectopic expression of FUS
enhances AR activity. 293FT cells in a 48 well plate were transfected with 15 ng AR expression plasmid, 620 ng ARR3-tk-luciferase reporter plasmid,
62 ng renilla luciferase plasmid and indicated amounts of His-FUS expression plasmid. Luciferase activities were normalized with those from renilla
luciferase that contains the minimal TK promoter. Values over each black bar represent fold-induction by R1881 after normalization (upper panel).
Western blot analysis of the corresponding samples show levels of FUS, AR, and ACTIN (middle panel). UT: untransfected cells. Renilla luciferase
activity from the same samples normalized to total protein served as a specificity control (lower panel). Columns=mean 6 standard deviation.
*P,0.05, n=3.
doi:10.1371/journal.pone.0024197.g004
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(a 526 aa long protein).
Expression of various co-regulators of AR is responsive to
androgens perhaps as part of feed-back mechanisms [15–17].
Expression of FUS is responsive to hormone status in prostate
cancer cells. At physiological levels of androgen, FUS expression
was reported to be significantly reduced in LNCaP cells treated
for 48–96 hrs with 10 nM mibolerone [21] as also shown here
with 10 nM R1881 (Fig. 7A). However, a lower concentration of
androgen, 0.1 nM R1881, did not significantly alter levels of FUS
in vitro,a n din vivo castrate levels of androgen were associated with
increased levels of FUS. This expression profile resembles that of
previously characterized AR co-activators that are modestly
repressed by androgens [15–16]. Interestingly, repression of these
co-activators by androgens is with a slower kinetics resembling
that of androgen-responsive expression of FUS. Analysis of levels
of FUS mRNA in various prostate and non-prostate cancer cell
lines did not reveal systematic differences (Fig S3). Consistent
with this, Oncomine data mining of microarrays from clinical
samples of various solid tumor types did not show significant up
or down-regulation FUS levels in prostate tumors relative to
other tumor types (Fig S4). In contrast, comparison of mRNA
data from benign versus adenocarcinoma prostate tissues
revealed up regulation of FUS in three independent studies and
no significant difference in four others. No study showed
significant decrease of expression of FUS in prostate adenocar-
cinoma versus benign tissue.
AR transcriptional activity is required for the maintenance and
growth of the prostate which forms the rationale for androgen
ablation therapies for prostate cancer. Consistent with FUS being
a coactivator of AR and its depletion reducing AR transcriptional
activity and androgen-dependent growth as shown here, among
the prominent phenotypes in FUS2/2 mice is male sterility, and
smaller male reproductive organs with apparent involution of
some of these structures [22]. These phenotypes are reminiscent of
AR2/2 mice, or more refined domain- and cell type-specific AR
gene disruptions [23–24]. Thus, it is possible that depletion of FUS
decreases AR transcriptional activity in these classical androgen-
dependent tissues in agreement with the data presented here.
These data are in contrast to a previous report that FUS
overexpression in LNCaP cells, using a tetracycline-inducible
system and subsequent treatment with 10 nM mibolerone for four
days, leads to emergence of sub-G1/apoptotic cells [21].
Intriguingly, no sub-G1/apoptotic cells were detected in the
absence of androgen, with or without FUS overexpression [21].
Thus, in those studies FUS overexpression led to an androgen-
inducible pro-apoptotic effect and changes in expression of cell
cycle proteins [21].
Overall, while further studies are needed to resolve the role of
FUS in prostate cancer disease progression, this study revealed
Figure 5. FUS enhances endogenous expression of AR target genes. (A) mRNA levels of androgen regulated genes. siRNA mediated
depletion of FUS decreases cognate mRNA for PSA and several other AR target genes. qRT-PCR was used to measure mRNA levels. Values represent
ratios of GAPDH-normalized signals to those derived from mock-transfected LNCaP cells. Cells were treated for 24 hrs following siRNA transfection.
(B) PSA protein levels. LNCaP cells were treated for 8 hrs with 10 nM R1881 or vehicle following siRNA transfection and Western blotting was
performed to measure PSA levels. (C) FUS is recruited to the enhancer ARE III of the PSA gene. LNCaP cells were treated with 10 nM R1881 for 6 hrs.
ChIP was subsequently applied and target DNA was amplified by qPCR. Values represent ratio of signals from anti-FUS ChIP to that of IgG isotype
control. Columns=mean 6 standard deviation. *P,0.05, n=3.
doi:10.1371/journal.pone.0024197.g005
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transcriptional activity of AR.
Materials and Methods
Plasmids, cell culture and transfections
FUS expression plasmids [20], p56Gal4UAS-TATA-luciferase
[12], and AR expression vector, ARO, [25] have been previously
described. PFR-LUC was obtained from Invitrogen, Carlsbad,
CA, USA. AR reporter plasmid, PSA (6.1 kb)-luciferase contains
the promoter/enhancer regions of the PSA gene and was provided
by Dr. J.-T. Hsieh (University of Southwestern Medical Center,
Dallas, TX). ARR3-tk-LUC contains three copies of androgen
response region of the rat probasin gene fused to the basal
thymidine kinase (TK) promoter [26].
LNCaP cells, obtained from Dr. Leland W.K. Chung (Samuel
Oschin Comprehensive Cancer Institute, CA, USA), were grown
in RMPI containing 5% Fetal Bovine Serum (FBS) and were used
at passage 39–50. HEK293 cells were maintained in DMEM
containing 10% FBS. Unless stated otherwise, cells were incubated
in serum-free, phenol-red free media for 24–48 hrs prior to
treatment with indicated concentrations of R1881. Transfection of
LNCaP cells was performed using lipofectamine 2000 (Invitrogen)
for experiments involving siRNAs or lipofectamine (Invitrogen) for
all others as per manufacturer’s instructions at 0.2–0.4% and 0.5%
(v/v), respectively. FUS (HSC.RNAI.N001170634.11.7;
HSC.RNAI.N001170634.11.8) and control siRNAs (Invitrogen)
were used at 10–50 nM concentrations. HEK293 cells were
transfected using lipofectamine 2000 at 0.4% v/v. Exact amounts
of plasmids per transfection are indicated in Figure legends.
Quantitative RT–PCR
Total RNA was prepared using the RNeasy mini kit (Invitrogen).
Total RNA (0.5 mg) was reverse-transcribed via oligo-dT priming
using the SuperScript III kit (Invitrogen). PCR was performed using
gene-specific primers in the presence of SYBR Green Supermix
(Invitrogen) using the ABI 7900 real-time PCR machine (Applied
Biosystems, Foster City, CA, USA). The thermocycling protocol
was as follows: at 95uC for 2 min, followed by 40 cycles of 95uC for
15 secand 55uC for30 sec.Ct (thresholdcyclenumber) valueswere
converted to mean expression values relative to GAPDH levels
according to the Pfaffl method. FUS primers [5] and all other
primers have previously been described [27–28].
Immunofluorescence
Cells were washed with PBS and fixed in 1% paraformaldehyde
in PBS for 30 min. Cells were permeabilized in 0.1% Trition X-100
in PBS twice for 5 min. After blocking for 30 minutes in 2% BSA in
PBS containing 0.1% Trition X-100, samples were incubated with
theindicated antibodies (1:50)in blockingbuffer for 1 hr.Cells were
washed with blockingbuffer 4 timesand incubated withappropriate
secondary FITC or rhodamine-conjugated IgG (1:100) in blocking
buffer for 45 min. After 4 washes with PBS containing 0.1% Trition
X-100, DAPI-containing mounting solution was added. Slides were
visualized using using Fluoview confocal microscope (Olympus,
Markham, ON, Canada).
Co-Immunoprecipitation and Chromatin
immunoprecipitation assay
LNCaP cells (2–3610
6) were plated in 15 cm dishes with RPMI
containing 5% FBS. After 24 hrs, media was changed into serum-
and phenol red-free RPMI and the cells were incubated for
additional 24 hrs. Cells were subsequently treated with R1881
(10 nM) or its vehicle (ethanol) for 6 hrs. Cells were rinsed with PBS
before harvesting and then lysed with 1 ml of lysis buffer (20 mM
Tris-HCl pH 7.8, 140 mM NaCl, 0.5% sodium deoxycholate,
0.5% Nonidet P-40) in the presence of a cocktail of protease
inhibitors (Roche, Mississauga, ON, Canada). Lysates were passed
through 27-G needles five times and were subsequently pre-cleared
with protein A/G agarose beads (5% v/v) and a mixture of mouse
and rabbit IgG (2 mg/ml each) for 1 hr. The resulting supernatant
was incubated with the indicated specific antibodies including AR
441, AR C19, and FUS ( Santa Cruz Biotechnology Inc, Santa
Cruz, CA, USA) at a concentration of 1–2 mg/ml for 16–24 hrs.
Protein A/G agarose beads (5% v/v) were subsequently added and
the mixture incubated for an additional 3 hrs. The beads were
washed with 1 ml of the lysis buffer five times and then resuspended
in 40–80 ml of standard SDS sample buffer.
Chromatin immunoprecipitation assay was performed as
described [27]. Briefly, cells were treated with R1881 (10 nM) or
vehicle for 6 hrs and were subsequently fixed with formaldehyde
to cross-link chromatin. After sonication to shear chromatin/
DNA, lysates were prepared and immunoprecipitated with the
indicated antibodies. Target DNA was measured by real time
PCR using the ABI 7900 real-time PCR machine (Applied
Biosystems, Foster City, CA, USA). Values were normalized
against signal from the respective IgG control.
Western blot analyses
Samples were loaded into 10% Tris/glycine-based SDS-
polyacrylamide gels. Proteins were transferred into polyvinylidene
difluoride membranes (Millipore, Billerica, MA, USA) according
to standard protocols using Tris/glycine-based transfer buffer in
Bio-Rad’s submarine system (Mississauga, ON, Canada). Blots
were probed with following antibodies: AR PG21 (1:1000)
(Upstate Biotechnology, Waltham, MA, USA); AR 441 (1:500),
or FUS 4H1 (1:1000) (Santa Cruz Biotechnology Inc).
Figure 6. The effects of FUS depletion on proliferation of
LNCaP cells. (A) Flow cytometric quantification of S-phase cells.
siRNA-transfected LNCaP cells were treated with 0.1 nM R1881 for
48 hours. Cells were labelled with BrdU, stained with FITC-conjugated
anti-BrdU antibody and DAPI, and subjected to flow cytometry. The
graph on the right represents quantification S-phase cells as a ratio to
the respective controls. *P,0.05, n=3. (B) Levels of FUS protein in cells
treated with FUS siRNA. Western blot analysis of levels of FUS and
loading control actin corresponding to the samples whose cell-cycle
profile is plotted in (A).
doi:10.1371/journal.pone.0024197.g006
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LNCaP cells (5610
5)i n1 0c mp l a t e sw e r et r a n s f e c t e dw i t h
siRNAs using lipofectamine 2000 (Invitrogen). After 24 hrs, the
media was changed into RPMI containing 10% charcoal-
stripped FBS and cells were incubated for additional 24 hrs
before treatment with 0.1 nM R1881 or equivalent amount of
ethanol. Two days pos-treatment, cells were allowed to
incorporate BrdU (Sigma, Oakville, ON, Canada) at 10 uM
for 3–4 hrs. Subsequently, cells were harvested, washed with
PBS and fixed with ethanol at 220uC for a minimum of 2 hrs.
Cells were washed and their DNA was denatured with 2 N
HCL, 0.5% Trition X-100 for 20 min. Following 4 washes, cells
were blocked with 4% FBS/0.1% Trition X-100 in PBS and
subsequently stained with 1:40 ant-BrdU antibody. After two
washes, DAPI was added at 2 ug/ml and samples were
subjected to flow cytometry.
In vivo experiments
Animal experiments were approved by the University of British
Columbia Animal Care Committee (Permit No. A05-1794), and
tissue processing thereafter was conducted as previously described
[29]. Immunohistochemistry was performed using anti-FUS (1:50)
(4H1; Santa Cruz Biotechnology, Inc) and anti-AR (1:50) (N-20;
Cruz Biotechnology, Inc) and detection was based on alkaline
phosphatase chemistry.
Supporting Information
Figure S1 Identification of FUS as AR -interacting
protein by co-immunopreciptation followed by mass
spectrometry (MS). MS/MS spectrum of m/z 2251.86 (from
751.63, 3+) of FUS was unambiguously assigned the identified
sequence APKPDGPGGGPGGSHMGGNYGDDR. Spectra for
two other peptides are shown in Figure 1 and Figure S2.
(TIF)
Figure S2 Identification of FUS as AR -interacting
protein by co-immunopreciptation followed by mass
spectrometry (MS). MS/MS spectrum of m/z 1407.64 (from
704.83, 2+) of FUS was unambiguously assigned the identified
Figure 7. Regulation of FUS expression. (A) FUS mRNA levels in response to androgen treatment. Upper panel: FUS expression was measured by
qRT-PCR in LNCaP cells treated with 10 nM R1881 for the indicated time points. Middle panel: western blot analysis of levels of FUS, PSA and Actin
proteins at the indicated time points. Lower panel: western blot analysis of levels of FUS protein in LNCaP cells that were treated with 10 nM versus
0.1 nM for 48 hrs. Error bars=mean 6 standard deviation. *P,0.05, n=3. (B) FUS levels in response to hormonal status in vivo. LNCaP xenografts
harvested from intact (non-castrated) and castrated mice (10 days post-castration) were stained for FUS and AR proteins. (C) FUS levels in clinical
prostate cancer versus corresponding benign tissue. Levels of FUS mRNA in clinical samples of prostate carcinoma versus normal prostatic tissue were
re-analysed from previously obtained data sets using Oncomine. Black bars indicate studies where FUS was significantly overexpressed in cancer
versus benign tissue. *P,0.05.
doi:10.1371/journal.pone.0024197.g007
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shown in Figure 1.
(TIF)
Figure S3 Comparative analysis of FUS expression in
various cancer cells. Cell lines representing various cancer
types were grown in their respective cell lines. Quantitative RT-
PCR was performed to quantify FUS mRNA relative to GAPDH.
LNCaP was used as reference for relative normalized expression.
Prostate cancer cell lines that are AR positive are shown in red and
in blue are AR negative prostate cancer cell lines. In black are
non-prostatic cancer cell lines. Columns=mean 6 standard
deviation. *P,0.05, n=3.
(TIF)
Figure S4 Comparative analysis of FUS expression in
clinical samples from various cancer types. Data from a
previous study is mined using Oncomine.
(TIF)
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